Table 1.
Baseline characteristics of the study population stratified by chemotherapy type.
| Variable | NA/DCT | ACT | All |
|---|---|---|---|
| Patients, n (%) | 40 (14.5) | 236 (85.5) | 276 (100) |
| VTE, n (%) | 5 (12.5) | 13 (5.5) | 18 (6.5) |
| Age (years) | |||
| Median | 62 | 65 | 64 |
| Range | 47–86 | 34–89 | 34–89 |
| BMI (kg/m2) | |||
| >30, n (%) | 23 (57.5) | 148 (53.6) | 171 (61.9) |
| Median | 31.3 | 32.3 | 32.1 |
| Range | 16.6–55.3 | 16.8–70.5 | 16.6–70.5 |
| Race/Ethnicity, n (%) | |||
| White | 32 (80) | 221 (93.6) | 256 (92.7) |
| Black | 6 (15) | 12 (5.1) | 18 (6.5) |
| Hispanic/Latino | 2 (5) | 1 (0.4) | 3 (1.1) |
| Other | 0 (0) | 2 (0.8) | 3 (1.1) |
| Current Smoker, n (%) | 1 (2.5) | 8 (3.4) | 9 (3.2) |
| Histology, n (%) | |||
| Endometrioid | 15 (37.5) | 101 (42.8) | 116 (42.0) |
| Serous | 13 (32.5) | 59 (25.0) | 72 (26.1) |
| Clear cell | 3 (7.5) | 3 (1.3) | 6 (2.2) |
| Mixed | 3 (7.5) | 35 (14.8) | 38 (13.8) |
| Carcinosarcoma | 2 (5) | 31 (13.1) | 33 (12.0) |
| Sarcoma | 1 (2.5) | 4 (1.7) | 5 (1.8) |
| Other* | 3 (7.5) | 3 (1.3) | 6 (2.2) |
| FIGO Grade, n (%) | |||
| 1 | 7 (17.5) | 52 (22.0) | 59 (21.3) |
| 2 | 3 (7.5) | 33 (14.0) | 36 (13.0) |
| 3 | 28 (70) | 148 (62.7) | 176 (63.8) |
| X | 2 (5) | 3 (1.3) | 5 (1.8) |
| FIGO Stage, n (%) | |||
| 1 | 2 (5) | 88 (37.3) | 90 (32.6) |
| 2 | 0 (0) | 8 (3.4) | 8 (2.9) |
| 3 | 4 (10) | 110 (46.6) | 114 (41.3) |
| 4 | 34 (85) | 30 (12.7) | 64 (23.2) |
| Hysterectomy, n (%) | 20 (50) | 233 (98.7) | 253 (91.7) |
| Residual Disease, n (%) | 25 (62.5) | 20 (8.5) | 45 (16.3) |
| Radiation, n (%) | 13 (32.5) | 146 (61.9) | 159 (57.6) |
| Blood Counts, n (%) | |||
| Platelet ≥ 350 x109/L | 18 (45) | 60 (25.4) | 78 (28.3) |
| Hgb ≤ 10 g/L | 14 (35) | 45 (19.1) | 59 (21.4) |
| WBC > 11 109/L | 11 (27.5) | 23 (9.7) | 34 (12.3) |
| Khorana Score ≥ 2, n (%) | 30 (75) | 161 (68.2) | 191 (69.2) |
| Khorana Score ≥ 3, n (%) | 18 (45) | 47 (19.9) | 65 (23.5) |
NA/DCT = neoadjuvant/definitive chemotherapy, ACT = adjuvant chemotherapy, FIGO = International Federation of Gynecology and Obstetrics.
*Other histologies includes dedifferentiated, undifferentiated and mucinous.